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Manipulation of pH responseCationic amphipathic pH responsive peptides possess high in vitro and in vivo nucleic acid delivery capabilities
and function by forming a non-covalent complex with cargo, protecting it from nucleases, facilitating uptake
via endocytosis and responding to endosomal acidiﬁcation by being released from the complex and inserting
into and disordering endosomal membranes. We have designed and synthesised peptides to show how
Coulombic interactions between ionizable 2,3-diaminopropionic acid (Dap) side chains can be manipulated to
tune the functional pH response of the peptides to afford optimal nucleic acid transfer and have modiﬁed the
hydrogen bonding capabilities of the Dap side chains in order to reduce cytotoxicity. When compared with
benchmark delivery compounds, the peptides are shown to have low toxicity and are highly effective at
mediating gene silencing in adherent MCF-7 and A549 cell lines, primary human umbilical vein endothelial
cells and both differentiated macrophage-like and suspension monocyte-like THP-1 cells.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
The great therapeutic potential of RNA interference (RNAi) is
threatened by waning interest from pharma in developing small
interfering RNA (siRNA) based drugs [1]. The root cause of much of
the frustration regarding the development of RNAi based therapies is
the inability to successfully deliver siRNA to target tissues [1]. Further,
gene knockdown experiments that are routinely performed in standard
cell lines are often difﬁcult to transfer to more biologically relevant
model systems including primary and/or suspension human cell types.
Of the numerous non-viral delivery systems, in particular cell-
penetrating peptides, conceived to overcome this hurdle [2–4], we
have focussed our attention on cationic amphipathic peptides con-
taining pH responsive residues that are capable of harnessing the
changes in pH associated with endocytosis and endosomal acidiﬁcation
to promote release of cargo to the cell cytosol [5,6]. These peptides are
capable of delivering plasmid DNA and siRNA to mammalian cell lines
in vitro with both high efﬁcacy and low associated toxicity [5–8], are
proven to deliver antisense oligonucleotides to patient derived primary
ﬁbroblasts [9] and have also been successfully applied in vivo to deliver44 207 848 4800.
. Open access under CC BY license.protein based vaccines adjuvantedwith Toll-like receptor 9 agonist CpG
oligonucleotide [10]. The observation that pH responsive peptides have
such properties has led us to consider how their delivery efﬁcacy can be
improved to enable delivery to suspension cell lines and primary cells
and hence widen the scope of potential in vivo applications. Though
sharing many properties with other polycationic delivery systems, the
pH responsive peptides have an additional functionality which leads
to a dramatic increase in gene delivery efﬁcacy when compared with
analogous peptides comprising cationic residues, such as ornithine or
lysine, which are not sensitive to pH changes in the desired range
[11–13]. This behaviour is linked to pH dependent changes in con-
formation in solution [13], topology [14], disordering activity [11,15]
in the target endosomal membrane and nucleic acid binding afﬁnity
[15,16].
To understand the role of the pH response in determining delivery
efﬁcacy, the behaviour during endosomal acidiﬁcation must be con-
sidered. Acidiﬁcation of the endosomes causes a dramatic change in
the charge state of the carrier peptides as it switches from a nominal
charge state of +5 to either +9 or +11, depending on the number of
pH responsive residues that have been incorporated. Since electrostatic
interactions determine much of the binding afﬁnity of the peptide for
the nucleic acid, the afﬁnity for each peptide for the cargo increases
[15,16] even though the actual effect on the complex is a release of
peptides [16]. Since the complex is fully saturated with peptide at
neutral pH, all possible binding opportunities between nucleic acid
and peptide are fulﬁlled. When the cationic charge on the peptide
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bound peptides can now be accommodated by the nucleic acid as the
charge state of the nucleic acid and the number of possible electrostatic
interactions remain unchanged [16]. Increasing the complement of pH
responsive residues should enhance peptide release from peptide–
nucleic acid complexes and consequent endosomal membrane dis-
ordering and delivery. However, a further hurdle exists since the
peptides may exist either as monomers or small aggregates in aqueous
solutions [17]. Coulombic interactions, which exist between the
protonated histidine residues when the peptide adopts an α-helix
conformation in its self-associated state, constitute such a barrier that
the protonation of the histidine residues and concomitant dissociation
of the peptide into the monomeric and membrane accessible form
may occur at a pH that is not achievable in endosomes when the
histidine content is increased [15]. Increasing the histidine content
also reduced the size of siRNA/peptide complexes and this, together
with the more acidic response, altered the uptake route of this cargo
leading to much poorer than expected delivery [8].
Dap rich peptides respond at a higher pH than histidine containing
analogues [13] but still respond in a range that could be exploited to
drive endosomal release and this suggests a hypothesis: the same
Coulombic interactions that acidiﬁed the pH response of histidine
enriched peptides to a point that they were unable to act in the
endosomes can be used to optimise the pH response of Dap enriched
peptides (Fig. 1A). Increasing the number of Dap residues will have
the added beneﬁt that the change in nominal charge state during
acidiﬁcation would be increased (+5 to +11 rather than +9) and3 4 5 6 7 8 9
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Fig. 1. Manipulating the pH response of Dap rich peptides. A surface representation of
LADap(Me)4-L1 (left) and LADap(Me)6-L1 modelled as α-helices that likely exist in an
oligomeric state at neutral to basic pH in suspension (A). Coulombic interactions
potentially exist between the twopairs or two triads of ionisableDap(Me) residues located
close to each other on one surface of the amphipathic α-helix and will be greater for
LADap(Me)6-L1. The change in CD at 220 nm for four peptides in aqueous suspension as
detected by far-UV CD spectroscopy is plotted as a function of pH; LADap4-L1 (dark
cyan) and LADap6-L1 (blue) (B), LADap(Me)4-L1 (dark cyan) and LADap(Me)6-L1
(blue) (C). Increasing the complement of either the primary amine Dap (B) or the N-
methylated Dap(Me) (C), from four to six residues, causes a notably more acidic
conformational response.more peptides theoretically released to afford much better endosomal
escape and nucleic acid delivery. We further hypothesised that the
observed higher toxicity of Dap in its primary amine form [13] would
be mitigated by interrupting inter-molecular hydrogen bonding
networks through alkylation of Dap side chain amino groups.
Having prepared peptides to test these hypotheses, wemonitored the
pH dependent conformational switches of a series of Dap rich peptides
with varying numbers of pH responsive elements and N-alkylation
using CD spectroscopy in aqueous solution. The strongly beneﬁcial effect
of thesemodiﬁcations on both peptidemediated plasmid DNA and siRNA
transfer is shown for a range of adherent cell lines including A549
adenocarcinomic human alveolar basal epithelial cells, MCF-7 human
breast cancer cells, human umbilical vein endothelial cells (HUVECs)
and differentiated THP-1 cells. Dap rich peptides with a tuned pH re-
sponse are, in particular, also highly effective at mediating siRNA transfer
to suspension monocyte THP-1 cells.
2. Material and methods
2.1. Materials
The peptides comprising natural amino acids (Table 1) were
purchased from Pepceuticals Ltd (Nottingham, UK) as desalted grade.
Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Boc-Lys(Boc)-OH·
DCHA, NovaSyn TGR resin with a modiﬁed Rink linker and (2-(6-
Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexaﬂuo-
rophosphate) (HCTU) Fmoc-Dap(ivDde)-OH were purchased from
Merck BioSciences, NovaBiochem (Nottingham, UK) and AnaSpec
(Fremont, CA). Peptide synthesis grade dimethylformamide (DMF),
Oxyma, diisopropylcarbodiimide, 2,4,6-collidine and hydroxybenzo-
triazole were purchased from Aldrich. All other reagents were of
analytical grade or better.
2.2. Peptide synthesis
NovaSynTGR resin with amodiﬁed Rink amide linker (0.22mmol/g)
was used for peptide synthesis on a 1mmol scale. Fmoc deprotection
was achieved with 20% piperidine in DMF (v/v) (2 × 7 min) and
acylation of Fmoc protected amino acids was achieved using HCTU
and collidine in the molar ratio (1:0.98:2) in peptide synthesis grade
DMF using a fourfold excess for 1 h under a nitrogen atmosphere.
Exceptionally, Fmoc Dap(Dde)OH was incorporated using a six fold
excess or with DCI and OXYMA in a six fold excess. The acylation of
Fmoc-Dap(Dde)-OH was extended for a minimum of 6 h. A Boc group
was incorporated at the N-terminus to avoid undesired alkylation of
the N-terminal lysine. Successful acylations and deprotections were
conﬁrmed by trinitrobenzene sulphonic acid (TNBS) test. Complete
deprotection of Dde protecting groups was achieved by incubation ofTable 1
Sequences of LAH or LADap derivatives used in this study. pH responsive residues are
marked in bold. The pKα quoted for the peptides is the midpoint of the main
conformational transition detected in solution using far-UV circular dichroism.
Peptide Sequence Length pKα at 37 °C
LAH KKLAHALHLLALLWLHLAHALKKA-NH2 24 5.33
LADap KKLAXALXLLALLWLXLAXALKKA-NH2 24 6.22±0.16
LADap(Me2) KKLAXALXLLALLWLXLAXALKKA-NH2 24 6.80±0.11
LAH4-L1 KKALLAHALHLLALLALHLAHALKKA-NH2 26 5.29±0.25
LADap4-L1 KKALLAXALXLLALLALXLAXALKKA-NH2 26 6.64±0.08
LADap(Me)4-L1 KKALLAXALXLLALLALXLAXALKKA-NH2 26 6.62±0.04
LAH6-L1 KKHLLAHLLHLLALLALHLLHALKHK-NH2 26 4.45±0.25
LADap6-L1 KKXLLAXLLXLLALLALXLLXALKXK-NH2 26 5.67±0.17
LADap(Me)6-L1 KKXLLAXLLXLLALLALXLLXALKXK-NH2 26 5.77±0.09
LADap(Me2)6-L1 KKXLLAXLLXLLALLALXLLXALKXK-NH2 26 n.d.
LADap(Me2)6-A1 KKXLLAXALXALLALLAXLAXALKXK-NH2 26 n.d.
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following a small scale cleavage and analytical RP-HPLC and MALDI-
TOF mass spectrometry.
2.3. Solid-phase N-methylation of DAP residues
Following removal of the Dde protecting group, resin bound LADap4-
L1 (200 mg, 44 μmol) was treated with 2-nitrobenzene sulphonyl
chloride (2-Nbs-Cl) (117 mg, 528 μmol) and collidine (106 mg,
880 μmol) in 3 ml DMF for 3 h. The resin was washed with DMF and
dichloromethane (DCM) before 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-
5-ene (MTDB) (821 mg, 528 μmol) and methyl 4-nitrobenzene
sulphonate (MSNBC) (191mg, 880 μmol) were added in 4ml DMF for
45 min and the resin washed again thoroughly with DMF and DCM.
20 eq. 1,8-diazabicyclo [5,4,0]undec-7-ene (DBU) (134 mg, 880 μmol)
and 2-mercaptoethanol (ME) (138mg, 1.76mmol) were added in 4ml
DMF and a distinct yellow colour was noted. After 45 min the resin
bound peptide was washed thoroughly with DMF, DCM and MeOH and
dried under vacuum.
2.4. Synthesis of NN-dimethylated Dap containing peptides
For the synthesis of LADap(Me2), Fmoc-Dap(Me2)-OH was in-
corporated in the presence of HOBt/DIPCDI in a 1:1 (v/v) DMF:DMSO
mixture. However, extensive recoupling was necessary to achieve
complete acylation as indicated by TNBS resin tests. For the synthesis
of LADap(Me2)6-L1 and LADap(Me2)6-A1 a solid-phase reductive
amination approachwasundertakenby adapting a previously described
method [18]. Resin bound LADap6-L1 (22 μmol) was swollen in THF
(0.5 ml) and treated with 37% aqueous formaldehyde (50 μl,
556 μmol) and 100 μl of a 1:1 (v/v) water:acetic acid solution. After
15min sodium cyanoborohydride (200 μl, 1M in THF) was added. The
reaction was shaken for 3 h, and then washed with THF, water, MeOH,
DCM and THF. The above procedure was repeated once more and the
mixture incubated overnight. Finally the resin waswashed as described
above and dried in vacuo.
2.5. Cleavage and puriﬁcation
The dried peptide resins were treated with TFA/phenol/H2O/
triisopropylsilane (87.5/5/5/2.5) for 2–3 h before ﬁltration into an
excess of ice cold diethyl ether. The precipitate was centrifuged into a
pellet and washed in an excess of fresh ice cold diethyl ether; this was
repeated three times and ﬁnally the precipitated peptide was dissolved
in 0.1% TFA and freeze-dried. Puriﬁcation for both purchased and in
house synthesised peptides was performed using water/acetonitrile
gradients using either a Waters Symmetry™ C8, 5 μm, 7.8 × 100 mm
column or a Waters SymmetryPrep™ C8, 7 μm, 19×300mm column.
3. Results
3.1. Peptide design
A series of eleven cationic amphipathic peptides was used in the
present study (Table 1) based upon either the most potent nucleic
acid delivery peptide generated over previous studies, LAH4-L1 [11] or
a shortened version, LAH [13]. Designed to adopt an amphipathic α-
helix in membranes, when bound to nucleic acids and in a self-
associated state at high pH in aqueous media, the histidine residues
will segregate on one face and, in an idealised helical wheel
representation, present an angle of 80°. Here, we have studied the effect
of replacing histidine with Dap and its methylated derivatives to
determine their effect on the pH response of the peptide. The three
shortened peptides comprising 24 amino acids are an evolution of our
previous work [13] and are designed to show the effect of N,N-di-
methylation of the four Dap residues on the biophysical and genedelivery properties. To evaluate the potential for modiﬁed peptides to
provide signiﬁcant and substantial improvements in gene silencing
capabilities, further eight peptides were conceived using the LAH4-L1
sequence as a template. Two derivatives of this peptide with four pH
responsive residues were prepared; one comprising Dap (LADap4-L1)
and one comprising N-methylation of Dap (LADap(Me)4-L1). Our
previous work [13] suggested that peptides comprising four Dap
residues only would have a pH response that is a little high to function
optimally as a pH switch during endocytosis. However, further work
indicates that increasing the number of pH responsive residues from
four to six can cause a much more acidic pH response when the
hydrophobicity of the peptide is adjusted accordingly [15]. The ﬁnal
series of peptides therefore is based on a LAH6-L1 peptide, which has
been obtained by replacing two alanine residues with histidines,
rearranging the three C-terminal residues and adjusting the hydro-
phobicity of the peptide by replacing two further alanineswith leucines.
The resulting peptide has an average hydrophobicity of 0.02 on the
Eisenberg [17] scale and can be compared with LAH4-L1 at 0.05, LAH
at 0.027 and is slightly less hydrophobic than the LAH6 peptides in the
previous study [15]. The series comprising six pH responsive amino
acids is analogous to the series described above comprising four
residues with the exception that two di-methyl Dap derivatives
LADap(Me2)6-L1 and the more hydrophilic LADap(Me2)6-A1 were
successfully prepared.3.2. Peptide synthesis
The solid phase syntheses of short peptides containing a single
monomethylated, dimethylated and trimethylated Dap have previously
been reported and the synthesis of Dap has been achieved by ring
opening reaction of β-lactones derived from serine [18]. Furthermore
the 2-nitrobenzenesulphonyl group has been utilised for the mono
alkylation of the side chain amines using both solution and solid phase
[19]. Reductive amination protocols have been utilised for the synthesis
of alkylated amine side chains again both in solution and on the solid
phase [20–22]. However, while the amino acids derivatives are readily
accessible and can be incorporated into model peptides, their in-
corporation into complex peptides is more challenging. Incorporation
of Fmoc Dap(Boc)OH into the peptides described was straightforward;
however the incorporation of Fmoc Dap(Me2) was problematic with
incomplete acylations and required extended reaction times. A wide
range of activation chemistries was investigated in order to optimise
the reaction conditions. The best conditions were activation with DIC
and HOBt in a mixture of DMSO and DMF. In this work, we describe a
“three-birds in one-pot” solid-phase approach where we obtained three
different peptides, namely non-methylated-, N-methylated- and N,N-
dimethylated-Dap containing cationic amphipatic peptides from a single
assembled resin–peptide sequence. The synthetic route is summarized
in Scheme 1. Solid phase reactions were carried out by the synthesis of
the hexa-Dap(Dde) peptide and successful removal of the Dde group to
afford the hexaDap-amino peptide. Subsequently, sulphonylation with
2-nitrobenzene sulphonyl chloride followed bymethylation with methyl
4-nitrobenzene sulphonate and removal of the protecting group using
mercaptoethanol and base afforded the hexa-N-monomethylated-Dap
containing peptide. The hexa-N,N-dimethylDAP peptide was obtained
by reductive amination of the hexaDap-amino peptide with formal-
dehyde and sodium cyanoborahydride. The synthesised peptides were
puriﬁed by preparative HPLC and characterised by MALDI-TOF MS
(Supp. Fig. 1/2) with yields in the following ranges: non-methylated —
36–47%, N-methylated — 13–26%, N,N-dimethylated — 9%. To our
knowledge, this is the ﬁrst example ofmultiple and selectivemethylation
of a complex peptide using a solid-phase approach. The orthogonal
strategy could be applied to any peptide sequence and further expanded
to obtain diverse methylations by employing multiple and orthogonal
protecting groups.
Scheme 1. Overview of the synthetic route for obtaining three different peptides from a
single assembled resin–peptide sequence. The N-terminus and lysine residues were Boc
protected. Dap (X) is Dde protected and sequential treatment with three different
combinations of reagent provides either non-methylated-, N-methylated- or N,N-
dimethylated-Dap containing cationic amphipathic peptides.
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Though not apparent for LAH, in our previous study LADap was
observed to cause some cytotoxicity during transfection [13], which
we suspected could be ascribed to the four Dap primary amines.
Therefore, we ﬁrst investigated whether reducing hydrogen-bonding
opportunities at the Dap side chain amine would improve its tolerance
by cells in culture. Alkylation of the Dap primary amine may however
also impact on the pKa. Predictions for the side chain pKa obtained
using Marvin View 5.1.4 for three model compounds based on
2-acetoamido-3-aminopropanamide (Supp. Fig. 1A) show that the free
amine is predicted to have the lowest pKa, with the NN-dimethyl
derivative having a pKa approximately 0.6 units higher. Measurement
of side chain pKa in a peptide undergoing a conformational transition
associated with a change in aggregation state is hindered by the large
amounts of material required for potentiometric analyses and the
unfavourable line broadening observed in NMR for self-associated
peptides [13]. Instead, we have observed the cooperative, pH responsive,
change of conformation of cationic amphipathic peptides in aqueous
solution using far-UV CD (Supp. Fig. 1B/C). LADap (Sup. Fig. 1B) and
LADap(Me2) (Supp. Fig. 1C) adopt an α-helix conformation when
dissolved in neutral or slightly basic aqueous solution and, when titrated
with acid, an increasingly disordered conformation is observed. The CD
intensity at 220 nm is considered indicative of α-helix content and can
be plotted as a function of pH (Supp. Fig. 1D/E). The midpoint of this
conformational transition, pKα, has been observed to be closely related
to the side chain pKa when this latter information has been tractable
and is an important determinant of nucleic acid transfer efﬁcacy as it
describes the transition from a self-associated form which is the trigger
for effective disruption of the endosomal membrane [14,23]. Although
other interactions may be expected to contribute to the pKα when
compared with the pKa, an increase of the same magnitude (~0.6 pH
units) is seen in both the pKα for the Dap rich peptide and the pKa for
themodel compound following dimethylation (Supp. Fig. 1D/E; Table 1).
The pKα of LADap(Me2) is raised by N,N-dimethylation and is likely
to be too high to substantially aid endosomal release; dimethylation
nevertheless has beneﬁcial effects on the nucleic acid transfer prop-
erties of the resulting peptide. Delivery of luciferase reporter gene to
adenocarcinomic human alveolar basal epithelial A549 cells indicates
that both Dap rich peptides are effective at mediating gene transfer
but, when considered in terms of luciferase activity per mg of protein,their performance is substantially inferior to that of Lipofectamine
2000™ (4:1; volume to weight DNA) and LAH4-L1 (Sup. Fig. 1F).
However, the protein content of the cells, commonly used to calibrate
the amount of speciﬁc luciferase activity, can be misleading. When the
protein content of the wells is plotted and compared with that of
untreated cells (Sup. Fig. 1G), a clearer picture emerges indicating that
peptide-mediated nucleic acid transfer causes dose dependent
cytotoxicity. Transfected cells would not be expected to have lower
protein content than untreated cells and hence signiﬁcant reductions
in cell protein content are a strong indicator of cytotoxicity. LADap is
notablymore toxic to A549 cells when comparedwith the dimethylated
LADap(Me2). Accordingly, the transfection efﬁcacies of LADap and
Lipofectamine 2000™ (4:1) in this experiment are substantially
overstated. When luciferase activity is plotted per well (Supp. Fig. 1H),
not only is the robust and non-toxic transfection efﬁcacy of LAH4-L1
evident, offering a 13.0 fold improvement over Lipofectamine 2000™,
but also the advantages of LADap(Me2) over LADap are clear. The
luciferase delivery efﬁcacy of LADap(Me2) however was insufﬁcient for
it to be considered for siRNA delivery and further modiﬁcations were
conceived.
3.4. The pH response of Dap rich peptides can be tuned
Using LAH4-L1 as a template, we investigated the effect of replacing
histidine residues with either Dap or N-methyl Dap on the cooperative,
pH dependent, conformational response in solution and investigated
whether this conformational response could be tuned by increasing
the Dap complement in the peptide, and consequently increasing the
Coulombic interactions expected between Dap or Dap(Me) residues
located close to each other in space (Fig. 1A). At the same time, we
mitigated the expected reduction in hydrophobicity by increasing the
number of leucine residues at the expense of alanine residues. The
overall aimwas to obtain peptides with the appropriate hydrophobicity
to afford favourable interactions with nucleic acids and membranes,
switch from a nominal charge of +5 to +11 during endosomal
acidiﬁcation and have a conformational transition between pH 5 and
pH6.
Far-UV CD spectra were obtained for LAH4-L1, LAH6-L1 and the Dap
and mono-methyl Dap containing analogues in aqueous Tris amine
buffer at various pH (Supp. Fig. 4). The pH dependent conformational
responses, reﬂected in the CD intensity at 220 nm, were plotted and
revealed the effect of incorporating either four or six Dap or mono-
methyl Dap residues in the peptide primary sequence (Fig. 1; Table 1).
For LAH4-L1, the pKα=5.29±0.25 and is in agreement with previous
work while pKα=4.45±0.25 for LAH6-L1 is substantially higher than
that reported recently for LAH6 peptides of greater hydrophobicity
[14]. The response of LADap4-L1 at 6.64 ± 0.08 is substantially more
basic than the histidine-containing analogue. N-methylation of the
Dap side chain did not alter the pH response signiﬁcantly (Fig. 1B/C).
Notably however the two peptides containing six Dap or six N-methyl
Dap residues had a much more acidic response when compared with
the analogues comprising only four such residues with midpoints for
the conformational transition at pH = 5.67 ± 0.17 and 5.77 ± 0.09
respectively, a drop of ≈1 pH unit. Taken together this indicates that,
when located close together in space, increasing the number of pH
responsive residues can indeed be used to tune the pKα.
The pH response of the six N,N-dimethyl-Dap containing peptide,
LADap(Me2)6-L1, was not determined as this peptide was found to be
insoluble in aqueous media as the six N,N-dimethyl-Dap residues
increased the peptide hydrophobicity dramatically. The removal of
hydrogen-bonding opportunities from the Dap side chain had a
substantial effect on the peptide hydrophobicity, as suggested by the
large increase in the peptide retention time when analysed by HPLC
(Supp. Fig. 5). A further six N,N-dimethyl-Dap variant, LADap(Me2)6-
A1 was prepared in an attempt to circumvent this by reducing
the hydrophobicity by substituting four leucines with alanine.
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retention time reduced, this peptide remained insufﬁciently soluble for
biophysical or biological studies. LADap(Me2)6-L1 was however soluble
in 50% triﬂuoroethanol and a far-UV CD spectrum was obtained (Supp.
Fig. 6) which indicated the desired α-helix conformation would
theoretically be obtainable if it could be delivered to the endosomal
membrane.
We have previously linked themembrane disordering capabilities of
pH responsive peptide to their nucleic acid transfer capabilities [11] and
that the midpoint of the pH dependent peptide induced membrane
disordering pKmem reﬂects the contributions of both peptide and
membrane composition to the pH dependent membrane activity [15].
The incorporation of chain deuterated lipids such as POPC-d31 or
POPS-d31 along with cholesterol in lipid bilayers designed to mimic
the endosomal membrane allows the effect of pH dependent changes
in peptide behaviour on either zwitterionic or anionic lipids to be
monitored. 2H spin echo NMR spectra of multi lamellar vesicles are
characterised by a series of quadrupolar splittings that correspond to
the deuterated groups which are located at increasing depth in the
membrane and which decrease with magnitude towards the hydro-
phobic core of the membrane where groups are more disordered.
When order parameters are averaged over the whole acyl chain and
plotted as a function of pH, the effect of pH responsive peptides can be
observed (Supp. Fig. 7A/B). As observed previously for histidine rich
peptides [15], both LADap(Me)4-L1 and LADap(Me)6-L1 effectively
increase the disorder of such membranes at acidic pH with a
substantially more basic response detected for both peptides in anionic
membranes (Supp. Fig. 7B) compared with zwitterionic membranes
(Supp. Fig. 7A). Interestingly, in contrast with histidine rich peptides
(15), LADap(Me)6-L1 consistently responds at a more basic pH when
compared with LADap(Me)4-L1. This may be related to the exothermic
heat of binding resulting from electrostatic interactions between
peptide and lipids that develop at the membrane surface during
protonation that has been observed to be particularly strong for Dap
[24]. Nevertheless, both peptides are expected to be capable of
disordering their target membranes at pH that are readily achievable
during endocytosis.
3.5. The tuned pH responsive peptides have improved nucleic acid transfer
capabilities
The ability of the peptides to mediate nucleic acid transfer was ﬁrst
assessed by monitoring the delivery of luciferase reporter gene to both
A549 and MCF-7 human breast cancer cells (Fig. 2A). Lipofectamine
2000™ was used here as a benchmark and at an optimised volume to
weight DNA ratio of 2:1 to minimise toxicity seen in the earlier
experiments (Supp. Fig. 1H). LAH4-L1 was effective at mediating
luciferase expression in both cell types but was somewhat inferior to
Lipofectamine 2000™ when used at the optimised ratios. Consistent
with the high pKα and the greater expected toxicity of the Dap side
chain free amine, LADap4-L1 was consistently less effective than
LAH4-L1 in mediating delivery to both cell types. However, N-
methylation of the Dap side chain led to a substantial improvement in
delivery with LADap(Me)4-L1 providing a 4.1 and 2.0 fold improve-
ment over LADap4-L1 and LAH4-L1 respectively for MCF-7 cells
(p b 0.05) and efﬁcacy that matched that of LAH4-L1 for A549 cells.
Increasing the Dap or N-methyl Dap content in the peptide and the
concomitant acidiﬁcation of the conformational response led to a
further increase in peptide mediated luciferase expression with the N-
methylated peptide again offering the better performance. LADap(Me)
6-L1 provided an 8.0 or 19.7 fold improvement over LADap4-L1 and a
2.1 or 2.6 fold improvement over Lipofectamine 2000™ for MCF-7 or
A549 cells respectively which was also signiﬁcant (pb0.05).
The abilities of the peptides to successfullymediate speciﬁc silencing
of GAPDH expression were then assessed in A549 cells (Fig. 2B), MCF-7
cells (Fig. 2C), HUVEC (Fig. 3A), THP-1 cells differentiated intomacrophages (Fig. 4A) and undifferentiated THP-1 cells in suspension
(Fig. 4B). Speciﬁc reductions in expression of GAPDH were assessed by
densitometry of Western blots where the effects of administering siRNA
targeting GAPDH was compared with that of non-targeting siRNA on
the expression of GAPDH as endogenous reporter and β-actin as internal
toxicity/speciﬁcity control (Figs. 2D, 3B, 4C). Lipofectamine 2000™
was used as a benchmark for A549 cells, MCF-7 cells, HUVECs and
differentiated, adherent THP-1 cells but was unsuited for use with
suspension THP-1 cells where the majority of cells were killed and
insufﬁcient protein for Western blots obtained; siPORT was used as
benchmark in its place and, for comparison, also with differentiated
THP-1 cells. For A549 andMCF-7 cells, all ﬁve peptidesmediated effective
reductions in GAPDH expression but no signiﬁcant improvements over
LAH4-L1 or Lipofectamine 2000™were observed (Fig. 2B–D).
To test the suitability of the peptides for future pulmonary delivery
applications in vivo the ability of the peptides to mediate silencing of
GAPDH expression in A549 cells was repeated in the presence of
bronchoalveolar lavage ﬂuid (BALF) as amodel for airway surface liquid
(ASL) (Fig. 2E/F). As shown in theWestern blot (Fig. 2E) and subsequent
densitometry (Fig. 2F), increasing the percentage of BALF in the
transfection medium caused a clear dose dependent reduction in gene
silencing efﬁcacy. This was most evident for LADap4-L1 with 50% BALF
causing substantial attenuation of the GAPDH silencing. Whereas for
LADap(Me)6-L1 the effect of BALF was minor and an effective reduction
of GAPDH expression by 70.6% was maintained, linked to the ability of
this peptide to mediate greater uptake of peptide/siRNA complexes
into the cells (Supp. Fig. 13). Increasing the number of Dap or Dap(Me)
residues from four to six conferred substantial and signiﬁcant
(p b 0.05) protection from the inhibitory effects of BALF although any
enhanced gene silencing attributable to N-methylation of Dap under
these conditions was not signiﬁcant.
The ability of the peptides to mediate silencing of GAPDH expression
was then tested in adherent, primary HUVECs. These hard to transfect
cells required much higher siRNA concentrations with as much as
150 nM siRNA necessary for notable speciﬁc silencing to be observed
(Fig. 3A). Nevertheless densitometry of themembrane (Fig. 3B) indicates
the peptides performed well in comparison with the Lipofectamine
2000™ benchmark, with LADap(Me)6-L1 again mediating the most
effective gene silencing and offering a signiﬁcant improvement on the
LAH4-L1 template peptide (p b 0.05). Importantly, the highly effective
gene silencing afforded by the pH responsive peptides did not come at
the expense of high cytotoxicity (Fig. 3C). For Lipofectamine 2000™,
only 70.9 ± 4.1% cell viability was retained after treatment whereas
each of the pH responsive peptides offered an improvement (p b 0.05)
with cell viability remaining between 80.8 and 91.5%. Interestingly,
while tuning the pH response, by increasing the Dap or Dap(Me)
content from four to six residues, did not have a clear effect on GAPDH
silencing efﬁcacy, a possible beneﬁcial effect on reducing cytotoxicity
was detected with LADap(Me)6-L1 causing less cytotoxicity than
LADap(Me)4-L1 (p b 0.05) and LADap6-L1 causing less than
LADap4-L1 (p=0.059).
The peptides were effective at mediating speciﬁc silencing of GAPDH
expression in both differentiated, adherent, macrophage and suspension,
monocyte THP-1 cells (Fig. 4A–C). For differentiated, adherent, macro-
phage THP-1 cells, effective silencing of GAPDH expression was observed
only for Dap or Dap(Me) rich peptides when six of these residues
were incorporated in the peptides with four residues conferring much
poorer siRNA transfection capabilities (Fig. 4C). Both LADap6-L1 and
LADap(Me)6-L1, alongwith the original LAH4-L1 template, outperformed
siPORT when delivering siRNA at 100 nM but not at 50 nM, while the
performance of Lipofectamine 2000™ was quite variable. For the THP-1
cells cultured in suspension as a model for monocytes, siRNA was
administered at either 20 or 40 nM, in three independently repeated
experiments, and a signiﬁcant (p b 0.05) improvement over LAH4-L1
and siPORT was observed (Fig. 4C). When siRNA was administered at
20 nM, two Dap rich peptides had an improved performance while at
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Fig. 2. Nucleic acid transfer activity to various cell lines. Transfection of MCF-7 or A549 cells with a luciferase reporter gene by Lipofectamine 2000™, LAH4-L1 and a variety of Dap and N-
methyl-Dap rich peptides (A). Speciﬁc knockdown of GAPDH in A549 (B) and MCF-7 (C) cells mediated by four Dap or Dap(Me) rich peptides or Lipofectamine 2000™ benchmarks and
assessed byWestern blot 72h post transfection. Cells were transfectedwith peptide/siRNA complexes containing GAPDH siRNA (+) or negative control siRNA (−) and β-actin served as
an internal control for equal protein loading and off target effects. Densitometry results are shown as an average of three independently repeated experiments (D). The effect of 0, 25 or 50%
bronchoalveolar lavage ﬂuid (BALF) on siRNA transfection of A549 cells is shown byWestern blot (E) and its densitometry (F). (*) and (+) pb0.05 improvement relative to LAH4-L1 and
LADap4-L1 respectively.
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Interestingly, N-methylation of the Dap sidechain caused a substantial
and signiﬁcant (pb 0.05) improvement in GAPDH silencing whether thepeptides contained four or six pH responsive units; LADap(Me)6-L1
was the best performing peptide reducing GAPDH expression by
92.3±3.7%.
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Fig. 3. Speciﬁc knockdown of GAPDH in HUVECsmediated by four Dap or Dap(Me) rich peptides or Lipofectamine 2000™ benchmark and assessed byWestern blot either 72 or 48h post
transfection for cells transfectedwith 100 or 150nMsiRNA respectively (A). Cells were transfectedwith peptide/siRNA complexes containing GAPDH siRNA (+) or negative control siRNA
(−) and β-actin served as an internal control for equal protein loading and off target effects. Densitometry results are shown as an average of three independently repeated experiments
(B). (*) p b 0.05 improvement relative to LAH4-L1. Toxicity of non viral vectors to HUVECs was assessed using the MTT assay 24h after a 4 h incubation in serum free media (C). Vectors
were prepared as for siRNA transfection experiments with 150 nM siRNA and a peptide to siRNA weight ratio of 10:1.
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macrophage THP-1 cells treated with the peptide and benchmark
vectors was tested using the colorimetric MTT assay in the presence
and absence of siRNA cargoes (Fig. 4D). Differentiated, adherent,macro-
phage THP-1 cells tolerated the vectors reasonably well but signiﬁcant
reductions in viability (pb0.05) of between 19 and 34% were observed,
with the presence or absence or cargo having little effect (Fig. 4D).
siPORT was much better tolerated by differentiated THP-1 cells and,
when formulated with siRNA, no signiﬁcant reductions in viability
were observed. However this vector performed poorly as an siRNA
transfection agent. In contrast, suspension, monocyte THP-1 cells were
much less sensitive to the peptide vectors (Fig. 4D) and although
reductions in viability were signiﬁcant for all but LADap6-L1, their
magnitude was substantially lower. Lipofectamine 2000™ was highly
toxic to the suspension THP-1 cells, conﬁrming the observation noted
when trying to use it as a benchmark in the corresponding siRNA
delivery experiments.
Finally the route of uptake of peptide/siRNA complexes was
monitored using live cell confocal microscopy with siRNA labelled
with Cy3 and acidic compartments, including mid to late endosomes
as well as lysosomes, labelled with LysoTracker® DND-26 (Fig. 5). In
our previous study [8] we found that differences in the distribution of
siRNA clusters were more notable after 20 h post transfection. The
entry of peptide/siRNA complexes to HUVECs mediated by either
LAH4-L1 (Fig. 5A–C) or LADap(Me)6-L1 (Fig. 5D–F) was monitored
24 h after transfection allowing the effect of chlorpromazine (Fig. 5B/
E) or nystatin (Fig. 5C/F) pre-treatment on uptake to be assessed. Both
peptides mediated effective uptake of Cy3-labelled siRNA with sub-
stantial co-localisation of red siRNA with green intracellular compart-
ments (Fig. 5A/D), particularly for LADap(Me)6-L1. Pre-treatment
with chlorpromazine had little effect on delivery to HUVECs mediated
by either peptide (Fig. 5B/E) in contrast with nystatin, which notably
affected delivery by both peptides but in different ways. For delivery
mediated by LAH4-L1, pre-treatment with nystatin caused an apparent
increase in co-localisation of siRNA containing complexes with acidic
compartments (Fig. 5C). Whereas, the same treatment leads to asubstantial reduction in uptake, with very little co-localisation detected,
when delivery was mediated by LADap(Me)6-L1 (Fig. 5F). Delivery of
Cy3 labelled siRNA to differentiatedmacrophage THP-1 and suspension,
monocyte THP-1 cells was monitored in a similar fashion (Supp.
Fig. 12). For macrophage THP-1 cells, co-localisation of complexes
with acidic compartments was less apparent when delivery was
mediated by LADap(Me)6-L1 when compared with LAH4-L1. The
method was insufﬁciently sensitive to detect uptake of siRNA into
suspension monocyte cells.
4. Discussion
Since the histidine rich predecessors of the Dap rich peptides
presented here have been successfully used to deliver a wide variety
of cargoes, without prior conjugation, both in an in vivo and in an
ex vivo study, we were interested to improve the capabilities of pH
responsive peptides such that not only ﬁbroblasts and other adherent
cell lines, but also suspension cell lines and primary cells become
tractable using this technology with robust gene silencing maintained
inmore challenging conditions. The pH responsive peptides are notable
in that they are capable of not only binding non-covalently and
condensing nucleic acids, preventing their degradation by endogenous
nucleases and promoting cellular uptake, but are also able to promote
escape from endosomes. The endosomal escape mechanism is likely to
be distinct from that of the proton sponge hypothesis that has been
established for other poly-cationic molecules although this may play a
role [25–28]; as analogous peptides, which do not undergo pH
dependent conformational changes, are much less effective at de-
livering nucleic acid cargo [13]. Our earlier observation, that Dap rich
peptidesmight respond topH changes in a range that could be exploited
to drive endosomal release, suggested that enhanced delivery ca-
pabilities could be obtained if the pH response could be tuned. In
practice, the Dap rich peptides behave similarly to their histidine
templates and the pH response, when the number of Dap residues is
increased from four to six, is acidiﬁed to the same extent as that
achieved in the histidine containing analogues. In contrast with the
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Fig. 4. Speciﬁc knockdown ofGAPDH in differentiated, adherentmacrophage (A) or suspensionmonocyte (B) THP-1 cellsmediated by four Dap or Dap(Me) rich peptides or Lipofectamine
2000™ or siPORT benchmarks and assessed byWestern blot 72h post transfection. Cellswere transfectedwith peptide/siRNA complexes containingGAPDH siRNA (+) or negative control
siRNA (−) and β-actin served as an internal control for equal protein loading and off target effects. Densitometry results are shown for as an average of three independently repeated
experiments (C). (+) and (*) p b 0.05 improvement relative to LAH4-L1 and Lipofectamine 2000™ or siPORT benchmarks respectively. Toxicity of non viral vectors to adherent
macrophage or suspension monocyte THP-1 cells was assessed using the MTT assay 24 h after a 4 h incubation (D). Vectors were prepared as for siRNA transfection experiments and
the peptide to siRNA weight ratio was 10:1 in all cases.
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rich peptides is reﬂected in the improved delivery of plasmid DNA
to A549 and MCF-7 cells and leads to substantial improvements in
siRNA delivery either under more challenging conditions or to more
challenging cell types.
While little difference between pH responsive peptideswas noted in
delivery of siRNA to either MCF-7 or A549 cells, substantial improve-
ments in delivery of siRNA to the latter were observed when
transfection was performed in the presence of lung surfactant con-
taining bronchoalveolar lavage ﬂuid (BALF) and mediated by Dap rich
peptides with a tuned pH response. With pulmonary siRNA delivery
an attractive route for the treatment of a wide variety of diseases
affecting the airway, pH responsive peptides have been formulated as
dry powders in a parallel study [29]. Transfections in the presence of
BALF are designed to model the likely barrier to transfection presented
by airway surface liquid (ASL). ASL covers the epithelial cells along the
respiratory tract and consists mainly of phospholipids and surfactant-
associated proteins which may affect the stability of siRNA/peptide
complexes and hence their delivery efﬁcacy [30,31]. Though delivery
of nucleic acids to A549 cells mediated by Lipofectamine 2000™ is
robust in the presence of BALF, the transfection efﬁciencywhen delivery
is mediated by histidine rich peptides is weak [29]. Here we show that
siRNA transfer in the presence of BALF is also weak for peptides
containing only four Dap or Dap(Me) residues but when these are
increased to six, good delivery efﬁcacy is maintained. These results are
in agreement with our earlier studies comparing plasmid DNA transfer[29] and highlight an advantage of tuning the pH response which is
only manifested in more challenging delivery conditions. N-methylation
of the Dap residues also offers a consistently observed enhancement in
delivery efﬁcacy.
The availability of cells derived from the human umbilical cord has
played an important role in the development of vascular biology.
HUVECs are endothelial cells that line the umbilical cord vein and
have provided a critical model that has enable breakthroughs in
understanding cellular and molecular events that underpin a wide
variety of disease processes [32] and are considered a hard to transfect
cell. They require elevated levels of siRNA for noticeable gene silencing
and this leads to substantial cytotoxicity when non-viral delivery
systems are used. Lipofectamine 2000™ offers robust gene silencing
under the conditions used in the present study, but this is accompanied
by substantial cytotoxicity. Gene silencing in HUVECs by Lipofectamine
2000™ is matched by the Dap or Dap(Me) rich peptides, with
LADap(Me)6-L1 the most effective. Furthermore, the gene silencing
mediated by the peptides comes with a much lower cytotoxicity cost
which was itself reduced through tuning the pH response in the
Dap(Me) rich peptides. HUVECs were also studied here using live cell
confocal microscopy to better understand the source of the improved
delivery efﬁcacy. In our previous study we demonstrated that, in MCF-
7 cells, the route of uptake for pH responsive peptide mediated siRNA
delivery differs from that for DNA delivery with the former preferring
clathrin independent endocytosis [8]. Furthermore, while caveolae
rather than clathrin dependent endocytosis was implicated in LAH4-L1
B CA
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Fig. 5. Live cell confocal imaging reveals differential localisation of LAH4-L1 or LADap(Me)6-L1 peptide/siRNA complexes (10:1 w/w) in HUVEC with reference to lysosomes. The effect of
treatment with chlorpromazine and nystatin is also shown. Cy3-labelled siRNA appears red while LysoTracker® DND-26, administered 5 min prior to imaging, appears green and
accumulates in cellular compartments with low internal pH. Images of HUVEC containing siRNA delivered by LAH4-L1 (A, B, C) and LADap(Me)6-L1 (D, E, F) are shown in the absence
(A, D) or presence of chlorpromazine (B, E) or nystatin treatment (C, F) 24 h after transfection. Scale bar=20 μm.
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peptide precluded entry via this mechanism and was suggested to be an
important contributory factor in the lower than expected delivery
efﬁcacy for such peptides [8]. In the present study, chlorpromazine has
little effect on uptake mediated by either LAH4-L1 or LADap(Me)6-L1,
conﬁrming that again clathrin mediated endocytosis does not provide
the major route of uptake for effective delivery mediated by either
peptide. Blocking caveolae dependent endocytosis of LAH4-L1/siRNA
complexes did not prevent uptake but led to a much greater co-
localisation with acidic compartments, most likely lysosomes. This
suggests that, analogous to polyplex uptake [33], when complexes can
enter via both clathrin and caveolae dependent endocytosis, blocking
the caveolae pathway may channel complexes to the lysosomal
compartments for degradation. Blocking caveolae dependent endocy-
tosis did not trigger the same increase in co-localisation of complexes
and lysosomes when delivery was mediated by LADap(Me)6-L1. This
could reﬂect either an inability of such complexes to enter via clathrin
dependent endocytosis, when the caveolae dependent pathway is
blocked, or a much greater ability to escape from acidic compartments.
The microscopy is unable to distinguish between these two possibilities
but in either case, with uptake mediated by both LAH4-L1 and
LADap(Me)6-L1 sensitive to blockage of caveolae dependent endocy-
tosis, the live-cell confocal imaging study indicates that uptakemediated
by peptides containing six Dap(Me) residues is likely to proceed in a
manner distinct from that of analogues containing six histidine residues
and suggests another important factor that contributes to their increased
siRNA delivery efﬁcacy.
The human monocytic leukaemia cell line THP-1 is widely used as a
model to probe either monocyte or macrophage biology [34]. A
substantial and useful improvement in siRNA delivery to macrophage
THP-1 cells also accompanied the tuning of the pH response in Dap orDap(Me) rich peptides but no improvement over the LAH4-L1 template
peptide was shown.
THP-1monocytes are of considerable interest since a wide variety of
diseases may beneﬁt from monocyte directed, siRNA based inter-
ventions. In particular, recent work has shown that silencing the
chemokine receptor CCR2 in inﬂammatory monocytes prevents their
accumulation in sites of inﬂammation in a mouse model [35]. The
beneﬁcial impact of this effect was demonstrated in models of
atherosclerosis, coronary artery occlusion, diabetes and tumour growth
[35]. Numerous other targets including, inter alia, Egr-1 for Alzheimer's
disease [36], hepcidin for anaemia of chronic disease [37] andWEE1 for
myeloid and lymphoid leukaemia [38] have been suggested following
studies on THP-1 cells and effective and non-perturbing delivery agents
to such cells are therefore highly sought after. While a large number of
non-viral siRNA delivery systems have been developed and are widely
used to mediate delivery to adherent cell lines, fewer options are
available for those working with suspension cell lines where typically
either lipid based transfection agents, such as Lipofectamine 2000™,
or electroporation are used [34] and, while an optimised lipid
nanoparticle has been successfully deployed to mediate silencing of
CCR2 in an inﬂammatory monocyte mouse model [35], there remains
a need to develop non-toxic agents that can routinely, robustly and
speciﬁcally effect gene silencing in monocytes both in vitro and in vivo.
Tuning the pH response of the Dap or Dap(Me) rich peptides had less
impact on delivery to monocyte THP-1 cells than that observed for
macrophage THP-1. Instead, the highly efﬁcient gene silencing mediated
by LADap(Me)4-L1 and LADap(Me)6-L1 rather demonstrated the
beneﬁts of N-methylation of the Dap side chain. These two peptides are
attractive candidates for further development for delivery to suspension
cells since they surpassed the two benchmark delivery compounds. The
relatively high cytotoxicity observed for Lipofectamine 2000™ precluded
938 V. Abbate et al. / Journal of Controlled Release 172 (2013) 929–938
G
E
N
E
D
E
L
IV
E
R
Yits use for siRNA delivery to monocyte THP-1 cells, with insufﬁcient
material recovered for Western blot experiments. In contrast, siPORT
was much gentler but suffered from poor gene silencing efﬁcacy.
In conclusion, using a global approach for on-resin, multiple and
selective N-methylation of peptides, we prepared a family of peptides
to show that overcoming the charge/self-association barrier by
replacing histidine with Dap or Dap(Me) and tuning the pH dependent
conformational response, by increasing the number of Dap or Dap(Me)
residues, directs uptake towards the caveolae dependent endocytosis
pathway and substantially improves the delivery capabilities of pH
responsive peptides. N-methylation of the Dap residues notably
increased gene silencing in monocyte THP-1 cells. The improvements
were sufﬁcient that the pH responsive peptides outperform the
benchmark liposomal delivery agents and are able to mediate highly
effective gene silencing with low associated toxicity, suggesting that
they will be adaptable for in vivo siRNA delivery.
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